Lest the auld year be forgot, ALS Today turns back the clock to toast the achievements and innovations in ALS in 2011 in this interactive timeline.

Emerging ALS mitochondrial-targeted medicines such as dexpramipexole are gathering steam. But, these medicines may need to do a lot more than boost energy production to stop the disease.

Changes in chemical modifications of the genome are emerging as important contributors to ALS. Possible cancer medicines are currently being evaluated to reverse some of these changes. But, according to a recent study, reducing DNA methylation may instead be a better way to go.

Scientists suspect that power outages in the motor nerves may contribute to ALS. But the power crews deployed to keep the energy flowing may actually fuel the progression of the disease according to a new study.

A growing number of neurologists are looking toward emerging combined MRI technologies to diagnose ALS more quickly and facilitate the development of new ALS medicines.

Methodist Neurological Institute’s Stanley Appel MD talks about the emerging role of cytotoxic microglia in ALS and potential treatment strategies to combat them looking forward.

A new study weighs in on whether the NeuRX DPS phrenic pacer improves the quality of life of people with ALS by focusing on sleep quality.

Dexpramipexole shows promise as a treatment for ALS according to phase II results published this week.